DRADP:NSD-Digirad Corporation

COMMON STOCK | Medical Devices |

Last Closing

USD 9.8

Change

+0.01 (+0.09)%

Market Cap

N/A

Volume

2.00K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-3.59 (-2.67%)

USD 51.34B
ALGN Align Technology Inc

-2.36 (-0.78%)

USD 22.68B
BRKR Bruker Corporation

-0.80 (-1.02%)

USD 12.93B
PODD Insulet Corporation

+1.52 (+0.92%)

USD 11.49B
SWAV Shockwave Medical Inc

+1.48 (+0.45%)

USD 10.25B
MASI Masimo Corporation

-1.15 (-0.85%)

USD 7.14B
AXNX Axonics Modulation Technologie..

-0.10 (-0.15%)

USD 3.42B
IRTC iRhythm Technologies Inc

-0.03 (-0.03%)

USD 3.36B
QDEL Quidel Corporation

+0.86 (+2.25%)

USD 3.14B
LIVN LivaNova PLC

-0.43 (-0.82%)

USD 3.02B

ETFs Containing DRADP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A F
Risk Adjusted Return N/A N/A N/A N/A F
Market Capitalization N/A N/A N/A N/A F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.